Avacta Group Plc (AVCT) Q4 2024 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Avacta Group Plc.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:01.010 -- 00:00:04.494 Good morning and welcome to the Evactor Group CLC investor presentation. 00:00:04.494 -- 00:00:07.537 Throughout the recorded presentation, investors will be in the scenario mode. 00:00:07.537 -- 00:00:11.380 Questions are encouraged and can be submitted at any time by the Q&A tab situated in 00:00:11.380 -- 00:00:14.744 the right corner of your screen. Simply type in your questions and press send. 00:00:14.744 -- 00:00:18.628 Due to the high attendance on today's call, the company may not be in a position to answer 00:00:18.628 -- 00:00:20.590 every question it receives in the meeting itself. 00:00:20.590 -- 00:00:23.813 However, the company can view all the questions submitted today and publish responses 00:00:23.813 -- 00:00:28.057 where it is appropriate to do so. Before we begin, I'd like to submit the following poll. 00:00:28.057 -- 00:00:30.340 I'd now like to hand over to CEO Christina Coughlin. 00:00:30.340 -- 00:00:32.500 Good morning. 00:00:33.730 -- 00:00:35.852 Good morning, and thank you for having us. 00:00:35.852 -- 00:00:40.957 I'm joined today by our Chief Financial Officer, Brian Hahn, and we will 00:00:40.957 -- 00:00:45.962 be presenting the fiscal year 2024 preliminary results 00:00:45.962 -- 00:00:48.604 for AVACTA Therapeutics. 00:00:48.604 -- 00:00:54.070 Let's jump in. We will be making forward-looking statements, and our disclaimer 00:00:54.070 -- 00:00:57.731 is noted here on the second slide. 00:00:59.135 -- 00:01:03.877 Let me start with a few of the highlights for AVACTA. 00:01:04.088 -- 00:01:10.115 The company has essentially, over the last year, undergone 00:01:10.115 -- 00:01:15.282 a complete transformation, and we are now positioned as a pure play 00:01:15.282 -- 00:01:18.485 oncology biopharmac...